MET and non-small cell lung carcinoma: Although MET IHC data are generally related to MET-amplification, biomarker data from clinical studies have yet to elucidate the connections of MET-overexpression with MET-mutation or -amplification as predictive biomarkers and indicators of NSCLC dependence on MET-signaling [134].